

# **ENDOCERVICAL SAMPLING (CURETTAGE) HAS NO PLACE IN COLPOSCOPY PRACTICE: CON POSITION**

---

**Robert G. Pretorius, MD**

**Department Ob/Gyn**

**Southern California Permanente Medical Group-Fontana**

**9961 Sierra Ave.**

**Fontana, CA 92335**



# Disclosures

---

- **I am employed by the Southern California Permanente Medical Group (S.C.P.M.G.). I am on the board of Preventive Oncology International Inc. Preventive Oncology International Inc. has received unrestricted grant support or support “in kind” (reagents, testing) from Hologic Inc., Qiagen, Gen-Probe, Merck Inc., and BGI Shenzhen.**
- **My employment by S.C.P.M.G. and participation in Preventive Oncology International pose no conflict of interest with this presentation.**



# 2012 ASCCP CONSENSUS GUIDELINES

---

**“Endocervical sampling is preferred for women in whom no lesions are identified and for those with an inadequate colposcopy but is acceptable for women with an adequate colposcopy and a lesion identified in the transformation zone.”**

**Massad LS *et. al.* Obstet Gynecol 2013;121(4):829-46**



# PREVALENCE OF CIN 2+ AND PERCENT OF COLPOSCOPIES WITH CIN 2+ DIAGNOSED FROM CERVICAL BIOPSY < CIN 2+ AND ECC OF CIN 2+

STUDY	PREVALENCE CIN 2+	% CIN 2+ FROM CERVICAL BIOPSY < CIN 2+ WITH ECC OF CIN 2+
Gage JC, 2010	18.6% (2,443/13,115)	5.4% (132/2,443)
Pretorius RG, 2015	15.3% (2,840/18,537)	9.7% (274/2,840)

Gage JC *et. al.* Am J Obstet Gynecol 2010;203:481.e1-9

Pretorius RG *et. al.* J Low Genit Tract Dis 2015;19(4):278-81



**CIN 3+ FROM CERVIX < CIN 2 WITH ECC OF CIN 2+ AND CIN 3+ SOLELY FROM ECC OF CIN 2+ (CERVIX < CIN 2; ECC CIN 2+; CYTOLOGY LSIL, ASC-US, OR NEG; AND IMPRESSION < CIN 2)**

<b>% CIN 3+ FROM CERVIX &lt; CIN 2 AND ECC CIN 2+</b>	<b>% CIN 3+ SOLELY FROM ECC OF CIN 2+</b>
<b>7.2% (101<sup>A</sup>/1,398)</b>	<b>3.6% (50<sup>B</sup>/1,398)</b>

<sup>A</sup>13 of 101 CIN 3+ were invasive cervical cancer

<sup>B</sup>5 of 50 CIN 3+ were invasive cervical cancer

Reanalysis of data from Pretorius RG *et. al.* J Low Genit Tract Dis 2015;19(4):278-81



# YIELD OF CIN 3+ SOLELY FROM ECC OF CIN 2+ FOR SUBSETS OF COLPOSCOPY

SUBSET OF COLPOSCOPIES	YIELD CIN 3+ SOLELY FROM ECC OF CIN 2+
Colposcopic Impression Normal	0.30% <sup>1</sup> (23/7,600)
Colposcopic Impression Abnormal	0.25% <sup>1</sup> (27/10,937) <sup>1</sup> 0.30% vs. 0.25%, p=.47
Colposcopy Inadequate	0.57% <sup>2</sup> (10/1,759)
Colposcopy Adequate	0.24% <sup>2</sup> (40/16,778) <sup>2</sup> 0.57% vs. 0.24%, p=.01
Age ≥ 25 years	0.36% <sup>3</sup> (47/13,104)
Age < 25	0.06% <sup>3</sup> (3/5,432) <sup>3</sup> 0.36% vs. 0.06%, p<.001
Age ≥ 50 years	0.85% <sup>4</sup> (21/2,480)
Age < 50 years	0.18% <sup>4</sup> (29/16,057) <sup>4</sup> 0.85% vs, 0.18%, p<.001

Reanalysis of data from Pretorius RG *et. al.* J Low Genit Tract Dis 2015;19(4):278-81



# % OF COLPOSCOPIES WITH ECC AND % OF POSSIBLE CIN 3+ DETECTED SOLELY BY ECC

SUBSET OF COLPOSCOPIES WITH ECC	% OF COLPOSCOPIES WITH ECC	PERCENT OF POSSIBLE CIN 3+ DETECTED SOLELY BY ECC OF CIN 2+
All	100.0% (18,537/18,537)	100.0% (50/50)
Impression Normal	41.0% (7,600/18,537)	46.0% (23/50)
Inadequate	9.5% (1,759/18,537)	20.0% (10/50)
Age ≥ 25 years	70.7% (13,104/18,537)	94.0% (47/50)
Age ≥ 50 years	13.4% (2,480/18,537)	42.0% (21/50)

Reanalysis of data from Pretorius RG *et. al.* J Low Genit Tract Dis 2015;19(4):278-81



# 2012 ASCCP CONSENSUS GUIDELINES

---

“Endocervical sampling is preferred for women in whom no lesions are identified and for those with an inadequate colposcopy but is acceptable for women with an adequate colposcopy and a lesion identified in the transformation zone.”

**“At colposcopy, endocervical sampling is preferred for non-pregnant women age 25 years and older.”**





# % OF CIN 3+ DIAGNOSED AS A FUNCTION OF TYPE OF BIOPSY FOR SEVEN PHYSICIANS

PHYSICIAN	% CIN 3+ FROM COLPO-DIRECTED BIOPSY ± RANDOM BIOPSY AND ECC	% CIN 3+ SOLELY FROM RANDOM CERVICAL BIOPSY	% CIN3+ SOLELY FROM ECC
#1	65.4% (17/26)	19.2% (5/26)	11.5% (3/26)
#2	50.0% (18/36)	36.1% (13/36)	2.8% (1/36)
#3	28.6% (6/21)	33.3% (7/21)	33.3% (7/21)
#4	69.2% (63/91)	18.7% (17/91)	8.8% (8/91)
#5	92.9% (13/14)	7.1% (1/14)	0.0% (0/14)
#6	28.6% (2/7)	28.6% (2/7)	42.9% (3/7)
#7	81.5% (22/27)	7.4% (2/27)	7.4% (2/27)
ALL	63.5% (141/222)	21.2% (47/222)	10.8% (24/222)

Reanalysis of data from Pretorius RG *et. al.* J Low Genit Tract Dis 2011;15:180-9

